BioCopy AG

📍 Basel, Switzerland👥 38 employees💰 Last funded May 2021
Biotechnology Research🌐 biocopy.com
Website LinkedIn
BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in todays pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in BioCopy AG?
BioCopy AG has 1 investors on record on gritt.io.
When did BioCopy AG last raise funding?
The most recent investment in BioCopy AG recorded on gritt.io was in May 2021.
What industry is BioCopy AG in?
BioCopy AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is BioCopy AG based?
BioCopy AG is headquartered in Basel, Switzerland.